Last month, America was shocked by the case of Turing Pharmaceuticals. Turing, in a blatant show of monopoly muscle, purchased the rights to toxoplasmosis drug Daraprim, only to raise its price from $13.50/pill to $750/pill. For those of you keeping track, that’s a 5,000% price increase. I say “monopoly muscle” because despite the patent for Daraprim technically having expired, no company has yet developed a generic version, according to Techdirt. In other words, Turing has only a functional monopoly on the drug. Perversely, this is good news. The situation would be much, much worse if Daraprim’s patent were still active. And even though Turing’s particular abuse is the one that’s hit the news, the fact is that its abuse is one that goes not only tolerated, but enabled by our dysfunctional patent system on a regular basis.
top of page
Recent Posts
See AllUFPR Co-Chairs Stephanie Martz and Chris Mohr authored an op-ed in Real Clear Markets about newly proposed rules from the USPTO. Efforts that undermine our robust IPR system will make American busines
United for Patent Reform (UFPR) today issued the following statement in opposition of the recently introduced PREVAIL Act, a bill that would essentially repeal a fundamental pillar of the America Inve
United for Patent Reform (UFPR) today issued the following statement in opposition of the recently introduced Patent Eligibility Restoration Act of 2023, a bill that would reopen the floodgates for va
bottom of page